Genetics and Biochemistry of Antibiotic Production

Total Page:16

File Type:pdf, Size:1020Kb

Genetics and Biochemistry of Antibiotic Production Genetics and Biochemistry of Antibiotic Production Edited by Leo C. Vining and Colin Stuttard Dalhousie University Halifax, Nova Scotia, Canada Butterworth-Heinemann Boston London Oxford Singapore Sydney Toronto Wellington CONTENTS Preface xxi SECTION A. GENETIC AND ENVIRONMENTAL CONTROL OF ANTIBIOTIC PRODUCTION 1 Overview by Leo C Vining 1. Global Physiological Controls 9 Janice L. Doull and Leo C. Vining 1.1 Introduction 9 1.2 Regulatory Mechanisms 11 1.3 Operation of Global Control Systems 30 1.4 Global Control of Secondary Metabolism 40 References 54 2. Genetics of Antibiotic Production in Streptomyces coelicolor A3(2), a Model Streptomycete 65 David A. Hopwood, Keith F. Chater and Mervyn J. Bibb 2.1 Introduction 65 2.2 The Pathway Genes 69 2.3 Transition from Primary to Secondary Metabolism 85 2.4 Genes with Pleiotropic Effects on the Production of Antibiotics 87 2.5 Conclusion 96 References 97 xm xiv Contents 3. Autoregulators 103 Sueharu Horinouchi and Teruhiko Beppu 3.1 Introduction 103 3.2 Streptomycete Autoregulators 104 3.3 Genetics of A-Factor Biosynthesis 110 3.4 Binding Proteins 111 3.5 Regulatory Cascade for Streptomycin Biosynthesis 113 3.6 A Model for Regulation of Streptomycin Biosynthesis 115 3.7 Conclusions 117 References 118 SECTION B. PEPTIDE AND PEPTIDE-DERIVED ANTIBIOTICS 121 Overview by Leo C. Vining and Hans von Dohren 4. Peptides 129 Hans von Dohren 4.1 Introduction 129 4.2 Overview of Peptides from Bacilli 130 4.3 Genetics of Peptide Biosynthesis 133 4.4 Other Systems in Perspective 145 4.5 Regulatory Mechanisms in Peptide Producers 154 4.6 Enzymology of Peptide Biosynthesis 157 4.7 Towards the Design of Enzyme Systems 160 4.8 Summary 161 References 161 5. Peptidolactones 173 Ullrich Keller 5.1 Introduction 173 5.2 Biosynthesis of Acyl Peptidolactones 174 5.3 Aromatic Carboxylic Acid Activating Enzymes 177 5.4 Chromopeptidolactone Synthetases 183 5.5 Biosynthesis of Nonacyl Peptidolactones 188 5.6 Conclusions 192 References 193 6. Bialaphos 197 Charles J. Thompson and Haruo Seto 6.1 Introduction 197 Contents xv 6.2 Origin of the BA Carbon Skeleton 200 6.3 Biosynthesis via Phosphonopyruvate 200 6.4 Regulation 214 6.5 Resistance 215 6.6 Conservation of the BA Biosynthesis Genes 217 6.7 Implications for Metabolic Pathway Evolution 218 References 219 7. Thiopeptides 223 William R. Strohl and Heinz-Gunter Floss 7.1 Introduction 223 7.2 Biochemistry of Thiopeptides 225 7.3 Genetics of Resistance and Biosynthesis 231 7.4 Thiopeptide Resistance Genes in S. azureus 234 References 236 8. Beta-Lactams 239 Susan E. Jensen and Arnold L. Demain 8.1 Introduction 239 8.2 Penicillins, Cephalosporins and Cephamycins 240 8.3 Clavulanic Acid 250 8.4 Carbapenems 252 8.5 Monocyclic /3-Lactams 253 8.6 Regulation of /3-Lactam Biosynthesis 254 References 260 9. Glycopeptides 269 Milton J. Zmijewski, Jr. and Jeffrey T. Fayerman 9.1 Introduction 269 9.2 Genetics and Molecular Biology 270 9.3 Resistance 272 9.4 Biosynthesis 273 9.5 Concluding Remarks 279 References 279 10. Lantibiotics 283 Michael J. Gasson 10.1 Introduction 283 10.2 Lantibiotic Structures 285 10.3 Biosynthesis of Lantibiotics 288 10.4 Lantibiotic Biosynthesis Gene Organization 296 10.5 Genetic Elements Encoding Lantibiotic Genes 298 xvi Contents 10.6 Protein-engineered Lantibiotics 299 10.7 Lantibiotic Mode of Action 302 10.8 Concluding Remarks 302 References 303 11. Microcins 307 Felipe Moreno, Jose Luis San Milldn, Conception Herndndez-Chico and Roberto Kolter 11.1 Introduction 307 11.2 Discovery of Microcins 308 11.3 Microcins A, D and E 309 11.4 Microcins C and H 310 11.5 MicrocinB 311 11.6 ColicinV 313 11.7 Transcriptional Regulation 315 11.8 Chromosomal Microcin Genes in E. coli 315 11.9 Concluding Remarks 317 References 319 SECTION C. POLYKETIDE-DERIVED ANTIBIOTICS 323 Overview by Leo C. Vining and David A. Hopwood 12. Anthracyclines 331 C. Richard Hutchinson 12.1 Introduction 331 12.2 Discovery 332 12.3 Biological Activity 332 12.4 Fermentation 334 12.5 Biosynthesis 334 12.6 Genetics of Anthracycline Production 339 12.7 Production of New Anthracyclines 352 References 353 13. Tetracyclines 359 Vladislav Behal and Iain S. Hunter 13.1 Introduction 359 13.2 Biogenesis 360 13.3 Enzymes of Secondary Metabolism 361 13.4 Enzymes of Primary Metabolism 365 13.5 Cellular Location of Enzymes 366 13.6 Genetics and Molecular Genetics 366 Contents xvii 13.7 Regulation of Biosynthesis 374 13.8 Regulatory Mechanisms in the Mycelium 378 13.9 Supply of Antibiotic Precursors 379 13.10 Fermentation Analyses and Modelling 379 13.11 Production by Immobilized Cells 380 References 380 14. Macrolides 385 Leonard Katz and Stefano Donadio 14.1 Introduction 385 14.2 Cloning of Macrolide Biosynthesis Genes 387 14.3 Macrocyclic Lactone "Polyketide Synthases" 392 14.4 Modification of the Lactone Ring 403 14.5 Biosynthesis and Modification of Sugars 406 14.6 Resistance 410 14.7 Regulation 412 14.8 Future Prospects 413 References 415 15. Avermectins 421 Douglas J. MacNeil 15.1 Introduction 421 15.2 Biosynthesis 423 15.3 Genetics of Avermectin Biosynthesis 427 15.4 Conclusions 439 References 440 16. Polyethers 443 Ashley W. Birch and John A. Robinson 16.1 Introduction 443 16.2 Biochemical Aspects of Polyether Biosynthesis 445 16.3 Genetics of Polyether Biosynthesis 465 References 472 17. Ansamycins 477 JuiShen Chiao, TianHui Xia, BaiGen Mei, ZhiKun Jin and WeiLing Gu 17.1 Introduction 477 17.2 Organisms Producing Ansamycins 478 17.3 Rifamycin Biosynthesis 480 17.4 Regulation of Rifamycin and Macbecin Biosynthesis 484 17.5 Shikimate Pathway Regulation 484 17.6 Nitrogen Incorporation into Rifamycin 487 Contents \1.1 Nitrogen Assimilation 488 17.8 Nitrogen Control of Rifamycin Production 489 17.9 Effects of Inorganic Phosphate 492 17.10 Effect of B-Factor on Rifamycin Biosynthesis 493 17.11 Genetics of Rifamycin Biosynthesis 493 References 494 SECTION D. OTHER BIOSYNTHETIC GROUPS OF ANTIBIOTICS 4" Overview by Leo C. Vining 18. Chloramphenicol 505 Leo C. Vining and Colin Stuttard 18.1 Introduction 505 18.2 Biosynthesis 507 18.3 Genetics 512 18.4 Physiological Regulation 515 18.5 Resistance 523 References 527 19. Streptomycin and Related Aminoglycosides 531 Wolfgang Piepersberg 19.1 Introduction 531 19.2 Streptomycin: Occurrence and Biology 532 19.3 Biosynthesis in 5. griseus 534 19.4 Cloning and Analysis of str Genes 541 19.5 Regulation of Streptomycin Production Genes 553 19.6 Conclusions and Perspectives 561 References 562 20. Aminoglycosides and Aminocyclitols 571 Kunimoto Hotta, Julian Davies and Morimasa Yagisawa 20.1 Introduction 571 20.2 AGACs Isolated since 1981 573 20.3 Butirosin 578 20.4 Semisynthetic AGACs 579 20.5 Biosynthesis of the Astromicin (Fortimicin) Group 581 20.6 AGAC Resistance Genes other than Self-resistance Genes 586 20.7 Gene Cloning in Micromonospora Species 590 20.8 Concluding Remarks 592 Contents xix References 592 21. Polyoxins and Related Nucleosides 597 Kiyoshi Isono 21.1 Introduction 597 21.2 Polyoxins 598 21.3 Nikkomycins (Neopolyoxins) 607 21.4 PolyoxinN 611 21.5 Blasticidin S and Mildiomycin 611 21.6 Other Nucleoside Antibiotics Related to Polyoxins 614 21.7 Conclusions 614 References 615 22. Agrocins 619 Bruce G. Clare 22.1 Introduction 619 22.2 Agrobacterium species and Biovars 620 22.3 Agrocins: Chemistry, Bioactivity and Specificity 620 22.4 Agrocins: Genetics of Biosynthesis 623 22.5 Agrocins: Biochemistry and Biosynthesis 625 22.6 Agrocins and Agrocinopines: Genetics of Sensitivity 625 22.7 Agrocins: Biological Control 627 22.8 Conclusions 630 References 630 23. Isoprenoid Antibiotics 633 David E. Cane 23.1 Introduction 633 23.2 Isoprenoid Chain-elongation Enzymes 635 23.3 Sesquiterpene Synthases 642 23.4 What Next ? 649 References 651 Index 657.
Recommended publications
  • Choline Esters As Absorption-Enhancing Agents for Drug Delivery Through Mucous Membranes of the Nasal, Buccal, Sublingual and Vaginal Cavities
    J|A Europaisches Patentamt 0 214 ® ^KUw ^uroPean Patent O^ice (fl) Publication number: 898 Office europeen des brevets A2 © EUROPEAN PATENT APPLICATION @ Application number: 86401812.2 (3) Int. CI.4: A 61 K 47/00 @ Date of filing: 13.08.86 @ Priority: 16.08.85 US 766377 © Applicant: MERCK & CO. INC. 126, East Lincoln Avenue P.O. Box 2000 @ Date of publication of application : Rahway New Jersey 07065 (US) 18.03.87 Bulletin 87/12 @ Inventor: Alexander, Jose @ Designated Contracting States : 2909 Westdale Court CH DE FR GB IT LI NL Lawrence Kansas 66044 (US) Repta, A.J. Route 6, Box 100N Lawrence Kansas 66046 (US) Fix, Joseph A. 824 Mississippi Lawrence Kansas 66044 (US) @ Representative: Ahner, Francis et al CABINET REGIMBEAU 26, avenue Kleber F-75116 Paris (FR) |j) Choline esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities. @ Choline esters are used as drug absorption enhancing agents for drugs which are poorly absorbed from the nasal, oral, and vaginal cavities. ! r ■ i ■ I njndesdruckerei Berlin 0 214 898 Description CHOLINE ESTERS AS ABSORPTION-ENHANCING AGENTS FOR DRUG DELIVERY THROUGH MUCOUS MEMBRANES OF THE NASAL, BUCCAL, SUBLINGUAL AND VAGINAL CAVITIES 5 BACKGROUND OF THE INVENTION The invention relates to a novel method and compositions for enhancing absorption of drugs from the nasal, buccal, sublingual and vaginal cavities by incorporating therein a choline ester absorption enhancing agent. The use of choline esters to promote nasal, buccal, sublingual and vaginal drug delivery offers several advantages over attempts to increase drug absorption from the gastrointestinal tract.
    [Show full text]
  • W O 2015/175939 A1 19 November 2015 (19.11.2015) W I PO I P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2015/175939 A1 19 November 2015 (19.11.2015) W I PO I P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated,for every A61K 9/127 (2006.01) A01N 43/04 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US2015/03 1079 DO, DZ, EC, EE, EG, ES, Fl, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 15 May 2015 (15.05.2015) KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (25) Filing Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/993,439 15 May 2014 (15.05.2014) US (84) Designated States (unless otherwise indicated,for every 62/042,126 26 August 2014 (26.08.2014) US kind of regional protection available): ARIPO (BW, GH, 62/048,068 9 September 2014 (09.09.2014) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/056,296 26 September 2014 (26.09.2014) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: INSMED INCORPORATED [US/US]; 10 DK, EE, ES, Fl, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Finderne Avenue, Building N'10, Bridgewater, NJ 08807- LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, 3365 (US).
    [Show full text]
  • 206 Antibacterials
    206 Antibacterials Arbekacin Sulfate (rINNM) Profile Avilamycin is an antibacterial that has been used in veterinary ABK (arbekacin); AHB-DBK (arbekacin); Arbekacin Sulphate; Ar- HO medicine as a growth promotor. békacine, Sulfate d’; Arbekacini Sulfas; HABA-Dibekacin (ar- O bekacin); Sulfato de arbekacina. O-3-Amino-3-deoxy-α-D-glu- HH copyranosyl-(1→4)-O-[2,6-diamino-2,3,4,6-tetradeoxy-α-D- S N CH3 erythro-hexopyranosyl-(1→6)]-N′-[(2S)-4-amino-2-hydroxybu- H Avoparcin (BAN, USAN, rINN) tyryl]-2-deoxy-L-streptamine sulphate. O NH N CH3 Avoparcina; Avoparcine; Avoparcinum; Compound 254. O Арбекацина Сульфат O Авопарцин COOH C22H44N6O10,xH2S04. H3C CAS — 37332-99-3. CAS — 51025-85-5 (arbekacin). N NH2 H Profile Avoparcin is a glycopeptide antibiotic usually produced by Amy- Pharmacopoeias. Jpn includes the trihydrate. colatopsis coloradensis (Streptomyces candidus). It has been in- OH corporated into animal feedstuffs to promote growth. Profile NH2 OH ◊ There is evidence of cross-resistance between avoparcin and Aspoxicillin is a ureidopenicillin that has been given intrave- 1 nously in the treatment of susceptible infections. vancomycin. Suggestions that vancomycin-resistant organisms could enter the human population from the food chain as a result O OH O NH2 of the use of avoparcin as a growth promotor in animals2,3 were O disputed by the manufacturers of avoparcin.4,5 After a ban in the EU on the use of avoparcin as a growth promotor in animals H N H N O OH Astromicin Sulfate (USAN, pINNM) 2 2 there has been some evidence6 of a decrease in the occurrence of H2N Abbott-44747; Astromicin Sulphate; Astromicine, Sulfate d’; As- vancomycin-resistant enterococci in poultry meat.
    [Show full text]
  • THALMUUNTURUS009732370B2 (12 ) United States Patent (10 ) Patent No
    THALMUUNTURUS009732370B2 (12 ) United States Patent (10 ) Patent No. : US 9 , 732 , 370 B2 Jagesar ( 45 ) Date of Patent: Aug. 15, 2017 ( 54 ) METHOD FOR THE DETERMINATION OF ( 58 ) Field of Classification Search THE PRESENCE OF AN ANTIBIOTIC IN A None FLUID See application file for complete search history. (71 ) Applicant: DSM IP ASSETS B . V ., Heerlen (NL ) ( 56 ) References Cited ( 72 ) Inventor : Dhiredj Chandre Jagesar , Echt (NL ) U . S . PATENT DOCUMENTS 2007/ 0092929 A1* 4 / 2007 Dekker .. .. .. C12Q 1/ 18 ( 73 ) Assignee : DSM IP ASSETS B . V ., Heerlen (NL ) 435 / 32 ( * ) Notice : Subject to any disclaimer, the term of this patent is extended or adjusted under 35 FOREIGN PATENT DOCUMENTS U . S .C . 154 (b ) by 0 days . EP 0005891 A112 / 1979 EP 0285792 Al 10 / 1988 ( 21) Appl. No .: EP 0611001 AL 8 / 1994 14 /787 , 859 EP 1639122 A1 3 /2006 WO 2005005655 AL 1 / 2005 ( 22 ) PCT Filed : Apr. 30 , 2014 wo 2013057182 AL 4 /2013 ( 86 ) PCT No . : PCT/ EP2014 / 058778 OTHER PUBLICATIONS $ 371 (c ) ( 1 ) , ( 2 ) Date : Oct. 29 , 2015 International Search Report from corresponding PCT/ EP2014 / 058778 , mailed Jul . 23 , 2014 . Gilbertson et al. , “ Modified Microbiological Method for the Screen ( 87 ) PCT Pub . No . : WO2014 / 177597 ing of Antibiotics in Milk ” , 1995 , J. Dairy Sci , vol. 78 , PCT Pub . Date : Nov . 6 , 2014 XP27050235, pp . 1032 - 1038 . (65 ) Prior Publication Data * cited by examiner US 2016 / 0076071 A1 Mar . 17 , 2016 Primary Examiner — Kade Ariani ( 30 ) Foreign Application Priority Data (74 ) Attorney , Agent, or Firm - McBee Moore Woodward & Vanik IP , LLC ; Susan McBee ; Chester May 2 , 2013 (EP ) .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0346294 A1 SENGUPTA Et Al
    US 2016.0346294A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0346294 A1 SENGUPTA et al. (43) Pub. Date: Dec. 1, 2016 (54) TREATMENTS FOR RESISTANT ACNE Publication Classification (71) Applicant: VYOME BIOSCIENCES PVT. LTD., (51) Int. Cl. New Delhi (IN) A6II 3/55 (2006.01) A63L/92 (2006.01) (72) Inventors: Shiladitya SENGUPTA, Delhi (IN); A6II 47/08 (2006.01) Suresh Rameshlal CHAWRAI, Pune A6II 47/8 (2006.01) (IN); Shamik GHOSH, Delhi (IN); C07D 53/04 (2006.01) Sumana GHOSH, Delhi (IN); Nilu A6II 47/38 (2006.01) JAIN, New Delhi (IN); Suresh A6II 47/32 (2006.01) SADHASIVAM, Salem (IN); Richard A6II 47/36 (2006.01) BUCHTA, Melbourne (AU); Anamika A6II 47/02 (2006.01) BHATTACHARYYA, Delhi (IN) A6II 45/06 (2006.01) A6II 47/10 (2006.01) (73) Assignee: VYOME BIOSCIENCES PVT. LTD., (52) U.S. Cl. New Delhi (IN) CPC ............... A6 IK3I/55 (2013.01); A61K 45/06 (2013.01); A61K 31/192 (2013.01); A61 K (21) Appl. No.: 15/115,143 47/08 (2013.01); A61K 47/183 (2013.01); A61K 47/10 (2013.01); A61K 47/38 (2013.01); (22) PCT Fed: Jan. 29, 2015 A61K 47/32 (2013.01); A61K 47/36 (2013.01); PCT No.: PCT/N2O15/000057 A61K 47/02 (2013.01); C07D 513/04 (86) (2013.01) S 371 (c)(1), (2) Date: Jul. 28, 2016 (57) ABSTRACT (30) Foreign Application Priority Data The present disclosure relates generally to novel molecules, compositions, and formulations for treatment of bacterial Jan. 29, 2014 (IN) ............................. 269/DELA2014 infections in general and more specifically to bacterial Nov.
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open: first published as 10.1136/bmjopen-2018-027935 on 5 May 2019. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 26, 2021 by guest. Protected copyright. BMJ Open BMJ Open: first published as 10.1136/bmjopen-2018-027935 on 5 May 2019. Downloaded from Treatment of stable chronic obstructive pulmonary disease: a protocol for a systematic review and evidence map Journal: BMJ Open ManuscriptFor ID peerbmjopen-2018-027935 review only Article Type: Protocol Date Submitted by the 15-Nov-2018 Author: Complete List of Authors: Dobler, Claudia; Mayo Clinic, Evidence-Based Practice Center, Robert D.
    [Show full text]
  • MINIREVIEW Aminoglycoside Research 1975-1985: Prospects for Development of Improved Agents KENNETH E
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1986, p. 543-548 Vol. 29, No. 4 0066-4804/86/040543-06$02.00/0 Copyright © 1986, American Society for Microbiology MINIREVIEW Aminoglycoside Research 1975-1985: Prospects for Development of Improved Agents KENNETH E. PRICE Industrial Consultant, Microbiology and Antibiotic Chemistry, 201 Barnstable Ct., Camillus, New York 13031 INTRODUCTION Mueller-Hinton medium, were used to estimate relative potencies. The MIC50 of the gentamicin C complex (genta- Following the synthesis of amikacin and the discovery of micin C) was arbitrarily assigned a value of 1.0, and potency its unique properties in 1972 (16, 36), there were high values of all other AGs were calculated on the basis of their expectations that even more potent and broader-spectrum activity relative to this standard. aminoglycosides (AGs) could be synthesized or identified in Another important measure of the relative effectiveness of soil-organism screens. Consequently, existing research pro- marketed AGs is the degree of their susceptibility to the grams were scaled up, and some new ones were initiated. modifying action of microbially produced enzymes. The Such efforts were surely justified, because AGs had proven comparative response of each of the AGs to the 10 most fully over the preceding decade to be the principal weapon in the characterized enzymes was considered in this evaluation. armamentarium available for the treatment of seriously ill Enzymes included the AG phosphotransferases APH (3')-I, patients. This key role evolved because, as a class, AGs APH (3')-II, and APH (2"); the adenylyltransferases AAD possess many of the properties considered by infectious (4') and AAD (2"); and the acetyltransferases AAC (2'), disease specialists to be inherently associated with an ideal AAC (6'), AAC (3)-I, AAC (3)-II, and AAC (3)-III.
    [Show full text]
  • Prescription Medications, Drugs, Herbs & Chemicals Associated With
    Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus American Tinnitus Association Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, or by any means, without the prior written permission of the American Tinnitus Association. ©2013 American Tinnitus Association Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus American Tinnitus Association This document is to be utilized as a conversation tool with your health care provider and is by no means a “complete” listing. Anyone reading this list of ototoxic drugs is strongly advised NOT to discontinue taking any prescribed medication without first contacting the prescribing physician. Just because a drug is listed does not mean that you will automatically get tinnitus, or exacerbate exisiting tinnitus, if you take it. A few will, but many will not. Whether or not you eperience tinnitus after taking one of the listed drugs or herbals, or after being exposed to one of the listed chemicals, depends on many factors ‐ such as your own body chemistry, your sensitivity to drugs, the dose you take, or the length of time you take the drug. It is important to note that there may be drugs NOT listed here that could still cause tinnitus. Although this list is one of the most complete listings of drugs associated with tinnitus, no list of this kind can ever be totally complete – therefore use it as a guide and resource, but do not take it as the final word. The drug brand name is italicized and is followed by the generic drug name in bold.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • The Kanamycin Biosynthetic Gene Cluster from Streptomyces Kanamyceticus Microbiological Resources and Technology Laboratories, M
    VOL. 57 NO. 5, MAY 2004 THE JOURNAL OF ANTIBIOTICS pp. 351-354 The Kanamycin Biosynthetic Gene Cluster collection which is highly developed for kanamycin from Streptomyces kanamyceticus production, was cultivated in YEME liquid medium16) at 28℃ for 24 hours, after which time, genomic DNA was prepared using an ISOPLANT DNA extraction kit (Wako KOJI YANAI* and TAKESHI MURAKAMI Pure Chemicals, Japan). Genomic DNA was then partially digested with MboI, dephosphorylated with calf intestinal Microbiological Resources and Technology Laboratories, alkaline phosphatase, and subsequently ligated to SuperCos Meiji Seika Kaisha, Ltd., 788 Kayama, Odawara-shi, Kanagawa 250-0852, Japan 1 vector (Stratagene, USA) that had been digested with XbaI, dephosphorylated with bacterial alkaline phosphatase (Received for publication March 5, 2004) and then digested with BamHI. Following packaging of the ligated DNA into the head of λ phage using a Gigapack III in vitro packaging kit (Stratagene, USA), a cosmid library Kanamycin is an aminoglycoside antibiotic produced by was propagated using Escherichia coli XLI-Blue MRA. Streptomyces kanamyceticus1). Although it possesses broad The kmr gene encoding 16S rRNA methyltransferase was range antibacterial activity, bacteria resistant to this amplified by PCR using two primers (forward; 5'- antibiotic readily appear, and therefore its clinical use has ATGTCGCAGTCCGCGTCC-3', reverse; 5'- been restricted to tuberculosis. Resistant bacteria inactivate TCAGCCCTTCGTGACCACG-3'), and employed as a kanamycin by modifying its specific amino- or hydroxy- probe for the screening of the cosmid library using an ECL group using acetyltransferase, phosphotransferase and direct DNA/RNA detection system (Amersham nucleotidyltransferase2). Investigations concerning bacterial Biosciences, USA) according to the manufacturer's resistance mechanisms led to the development of semi- instructions.
    [Show full text]
  • Separation and Purification of Pharmaceuticals and Antibiotics [Table IX-1-1] Principal Antibiotics Penicillin-G (Benzylpenicillin), Oxacillin, Chlox- 1
    Separation and Purification of Pharmaceuticals and Antibiotics [Table IX-1-1] Principal Antibiotics Penicillin-G (benzylpenicillin), Oxacillin, Chlox- 1. Antibiotics acillin, Dichloxacillin, Nafcillin, Methicillin, (1) Outline Amoxicillin, Ampicillin, Ticarcillin, Piperacillin, Penicillins aspoxicillin, Antibiotics are "chemical substances produced by microorganisms Ciclacillin, Sulbenicillin, Talampicillin, which, in minute quantities, inhibit or suppress the proliferation of other Bacampicillin, Pivmecillinam, lenampicillin, microorganisms". This is defined in 1942 by Selman Abraham Waksman β-Lactams Phenethicillin, Carbenicillin etc, in the USA. Antibiotics were developed in Britain following the discovery Cephalosporin C of Penicillin in 1929 by Alexander Fleming: He found that Blue mold, Cefazolin, Cefatrizine, Cefadroxil, Cefalexin, Cephalosporins Cefaloglycin, Cefalothin, Cefaloridine, Cefoxitin, Penicillium, dissolves Staphylococcus staphylococci and inhibits its Cefotaxime, Cefoperazone, Ceftizoxime, Cefmet- growth and he named the extract from Penicillium as Penicillin. Many azole, Cefradine, Cefroxadine etc. new antibiotics have been found since 1940’s, and there are more than Other β-lactams 1,500 antibiotics. Principal ones are listed in Table IX-1-1. Kanamycins Amikacin, Kanamycin, Dibekacin Most of these antibiotics are manufactured by fermentation or by Gentamycins, Gentamicin, Micronomicin semi-synthesis that combines fermentation and organic synthesis, though Sisomycins chloramphenicol is by synthesis. Fermentation is carried out by Acti- Streptomycins Streptomycin Aminoglycosides nomycetes, mold (hyphomycetes) or bacteria in culture media with glu- Spectinomycins Spectinomycin cose, sucrose, lactose, starch or dextrin as carbon source, with nitrate, Fradiomycins Fradiomycin, ammonium salt, corn steep liquor, peptone, meat extract or yeast extract Astromicins Astromicin as nitrogen source and with a little amount of inorganic salts. Erythromycin, Oleandomycin, Carbomycin, Penicillin-type antibiotics are manufactured by semi-synthesis, i.e.
    [Show full text]
  • 6-Veterinary-Medicinal-Products-Criteria-Designation-Antimicrobials-Be-Reserved-Treatment
    31 October 2019 EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use Advice on implementing measures under Article 37(4) of Regulation (EU) 2019/6 on veterinary medicinal products – Criteria for the designation of antimicrobials to be reserved for treatment of certain infections in humans Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Introduction On 6 February 2019, the European Commission sent a request to the European Medicines Agency (EMA) for a report on the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans in order to preserve the efficacy of those antimicrobials. The Agency was requested to provide a report by 31 October 2019 containing recommendations to the Commission as to which criteria should be used to determine those antimicrobials to be reserved for treatment of certain infections in humans (this is also referred to as ‘criteria for designating antimicrobials for human use’, ‘restricting antimicrobials to human use’, or ‘reserved for human use only’). The Committee for Medicinal Products for Veterinary Use (CVMP) formed an expert group to prepare the scientific report. The group was composed of seven experts selected from the European network of experts, on the basis of recommendations from the national competent authorities, one expert nominated from European Food Safety Authority (EFSA), one expert nominated by European Centre for Disease Prevention and Control (ECDC), one expert with expertise on human infectious diseases, and two Agency staff members with expertise on development of antimicrobial resistance .
    [Show full text]